Current and historical daily PE Ratio for PFE (
Pfizer Inc
) from 1990 to May 05 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Pfizer stock (PFE) PE ratio as of May 05 2024 is 0.
More Details
Pfizer Inc (PFE) PE Ratio (TTM) Chart
Pfizer Inc (PFE) PE Ratio (TTM) Historical Data
View and export this data going back to 1990. Start your Free Trial
Total 1222
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Pfizer PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-05 | At Loss | 2024-03-01 | 73.9 |
| 2024-05-03 | At Loss | 2024-02-29 | 73.8 |
| 2024-05-02 | At Loss | 2024-02-28 | 75.1 |
| 2024-05-01 | At Loss | 2024-02-27 | 74.7 |
| 2024-04-30 | At Loss | 2024-02-26 | 75.5 |
| 2024-04-29 | At Loss | 2024-02-23 | 77.1 |
| 2024-04-26 | At Loss | 2024-02-22 | 76.5 |
| 2024-04-25 | At Loss | 2024-02-21 | 76.9 |
| 2024-04-24 | At Loss | 2024-02-20 | 76.6 |
| 2024-04-23 | At Loss | 2024-02-16 | 76.7 |
| 2024-04-22 | At Loss | 2024-02-15 | 76.4 |
| 2024-04-19 | At Loss | 2024-02-14 | 75.3 |
| 2024-04-18 | At Loss | 2024-02-13 | 74.9 |
| 2024-04-17 | At Loss | 2024-02-12 | 76.8 |
| 2024-04-16 | At Loss | 2024-02-09 | 76.6 |
| 2024-04-15 | At Loss | 2024-02-08 | 76.6 |
| 2024-04-12 | At Loss | 2024-02-07 | 76.6 |
| 2024-04-11 | At Loss | 2024-02-06 | 76.4 |
| 2024-04-10 | At Loss | 2024-02-05 | 73.8 |
| 2024-04-09 | At Loss | 2024-02-02 | 74.8 |
| 2024-04-08 | At Loss | 2024-02-01 | 75.8 |
| 2024-04-05 | At Loss | 2024-01-31 | 75.2 |
| 2024-04-04 | At Loss | 2024-01-30 | 75.1 |
| 2024-04-03 | At Loss | 2024-01-29 | 76.3 |
| 2024-04-02 | At Loss | 2024-01-26 | 76.3 |
| 2024-04-01 | At Loss | 2024-01-25 | 76.3 |
| 2024-03-28 | At Loss | 2024-01-24 | 78.7 |
| 2024-03-27 | 77.2 | 2024-01-23 | 79.0 |
| 2024-03-26 | 76.6 | 2024-01-22 | 78.6 |
| 2024-03-25 | 76.2 | 2024-01-19 | 78.6 |
| 2024-03-22 | 76.0 | 2024-01-18 | 78.0 |
| 2024-03-21 | 76.8 | 2024-01-17 | 78.2 |
| 2024-03-20 | 76.9 | 2024-01-16 | 78.7 |
| 2024-03-19 | 76.8 | 2024-01-12 | 79.7 |
| 2024-03-18 | 77.0 | 2024-01-11 | 78.9 |
| 2024-03-15 | 77.6 | 2024-01-10 | 80.5 |
| 2024-03-14 | 78.1 | 2024-01-09 | 81.7 |
| 2024-03-13 | 78.4 | 2024-01-08 | 82.2 |
| 2024-03-12 | 77.8 | 2024-01-05 | 81.9 |
| 2024-03-11 | 78.8 | 2024-01-04 | 80.8 |
| 2024-03-08 | 75.6 | 2024-01-03 | 82.6 |
| 2024-03-07 | 74.4 | 2024-01-02 | 82.6 |
| 2024-03-06 | 75.5 | 2023-12-29 | 80.0 |
| 2024-03-05 | 72.4 | 2023-12-28 | 80.0 |
| 2024-03-04 | 71.9 | 2023-12-27 | 15.6 |
Pfizer Inc (PFE) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Pfizer Inc
NAICS : 325412
SIC : 2834
ISIN : US7170811035
Share Class Description:
PFE: Ordinary SharesCompare
Compare
Traded in other countries / regions
PFE.USAPFE.Canada0Q1N.UKPFE.GermanyPFIZ34.BrazilPFE.ArgentinaPFE.Mexico1PFE.ItalyPFE.PeruPFE.ChilePFE.AustriaPFE_KZ.KazakhstanPFE.UkrainePFEBC.Belgium IPO Date
1951-06-22Description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers